Given that PLK1 inhibitors require phosphorylated, active PLK1 to exert their therapeutic effect, the absence of PLK1Thr210 in HBV-HCC may limit the utility of PLK1-directed therapies in this subgroup [24,25,52]. This evidence concerns the gene PLK1 and hepatocellular carcinoma.